Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer

Oncogene

Volumn 30, Issue 28, 2011, Pages 3186-3197

  Roberts, C G ^a   Millar, E K A ^a,b,c   O'Toole, S A ^a,d,e,f   McNeil, C M ^a,g,h   Lehrbach, G M ^a   Pinese, M ^a   Tobelmann, P ^a   McCloy, R A ^a   Musgrove, E A ^a,c   Sutherland, R L ^a,c   Butt, A J ^a,c  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g WESTMEAD HOSPITAL   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

breast cancer; PUMA; tamoxifen

Indexed keywords

AFIMOXIFENE; BH3 PROTEIN; CYCLOHEXIMIDE; ESTRADIOL; ESTROGEN; FULVESTRANT; MESSENGER RNA; PROTEIN P53; PUMA PROTEIN; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; DISEASE PROGRESSION; DOWN-REGULATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960371728     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.36     Document Type: Article

References (36)

1. Anderson LR, Sutherland RL, Butt AJ. (2010). BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation. Oncogene 29: 527-538.
2. Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL. (2008). Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 630: 189-205.
3. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. (2005). Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Rel Cancer 12: S47-S59. (Pubitemid 41395413)
4. Butt AJ, Musgrove EA, Sutherland RL. (2007). Live or let die: oestrogen regulation of survival signalling in endocrine response. Breast Cancer Res 9: 306.
5. Butt AJ, Roberts CG, Seawright AA, Oelrichs PB, MacLeod JK, Liaw TYE et al. (2006). A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 5: 2300-2309. (Pubitemid 44530467)
6. Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JMS. (2007). Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat 102: 173-179. (Pubitemid 46452171)
7. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J et al. (2006). Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38: 1289-1297. (Pubitemid 44646291)
8. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403. (Pubitemid 40193310)
9. Ellis MJ, Rosen E, Dressman H, Marks J. (2003). Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. J Steroid Biochem Mol Biol 86: 301-307. (Pubitemid 37412569)
10. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 18-27.
11. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle CR, Katzenellenbogen BS. (2003). Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562-4574. (Pubitemid 37204856)
12. Garrison SP, Jeffers JR., Yang C, Nilsson JA, Hall MA, Rehg JE et al. (2008). Selection against PUMA gene expression in Myc-driven Bcell lymphomagenesis. Mol Cell Biol 28: 5391-5402.
13. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. (2009). An online survival analysis tool to rapidly assess the effect of 22 277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 123: 725-731.
14. Hammerich-Hille S, Kaipparettu BA, Tsimelzon A, Creighton CJ, Jiang S, Polo JM et al. (2010). SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. J Biol Chem 285: 3608-3616.
15. Han J, Flemington C, Houghton AB, Gu Z, Zambettidagger GP, Lutz RJ et al. (2001). Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci USA 98: 11318-11323. (Pubitemid 32928726)
16. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 200: 57-70. (Pubitemid 30046295)
17. Hur J, Chesnes J, Coser KR, Lee RS, Geck P, Isselbacher KJ et al. (2004). The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc Natl Acad Sci USA 101: 2351-2356. (Pubitemid 38269315)
18. Hurvitz SA, Pietras RJ. (2008). Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 113: 2385-2397.
19. Jeffers JR., Parganas E, Lee Y, Yang C, Wang J, Brennan J et al. (2003). Puma is an essential mediator of p53-dependent and - independent apoptotic pathways. Cancer Res 52: 5204-5207.
20. Jordan VC. (2009). A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 69: 1243-1254.
21. Karst AM, Dai DL, Martinka M, Li G. (2005). PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene 24: 1111-1116. (Pubitemid 40313889)
22. Millar EKA, Anderson LR, McNeil CM, OToole SA, Pinese M, Crea P et al. (2008). BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Br J Cancer 100: 123-133.
23. Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC et al. (2008). Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 3: e2987.
24. Musgrove EA, Sutherland RL. (2009). Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643.
25. Nakano K, Vousden KH. (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694. (Pubitemid 32706359)
26. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE. (2008). The HER4/4ICD estrogen receptor coactivator and BH3- only protein is an effector of tamoxifen-induced apoptosis. Cancer Res 68: 6387-6395.
27. Perillo B, Sasso A, Abbondanza C, Palumbo G. (2000). 17b-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901. (Pubitemid 30183508)
28. Reimer T, Koczan D, Muller H, Friese K, Thiesen H-J, Gerber B. (2002). Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer. Breast Cancer Res 4: R9.
29. Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S. (1991). Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 88: 10657-10661. (Pubitemid 21915896)
30. Swaby RF, Sharma CG, Jordan VC. (2007). SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 8: 229-239. (Pubitemid 47524868)
31. van de Vijver MJ, He YD, vant Veer LJ, Dai H, Hart AA, Voskuil DW et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009. (Pubitemid 35461656)
32. Vousden KH. (2005). p53 and PUMA: a deadly duo. Science 309: 1685-1686. (Pubitemid 41285928)
33. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. (2003). PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100: 1931-1936. (Pubitemid 36254551)
34. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. (2001). PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7: 673-682. (Pubitemid 32706358)
35. Yu J, Zhang L. (2005). The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331: 851-858. (Pubitemid 40615516)
36. Yu J, Zhang L. (2009). PUMA, a potent killer with or without p53. Oncogene 27: S71-S83.